liudi yuan

Dr. liudi yuan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Journal of Drug Targeting
Verified
Journal Article
Closed access
MAMehwish Saba Aslam
Mehwish Saba Aslam
LYliudi yuan
liudi yuan
Serpina3n is a secretory serine protease inhibitor belonging to clade “a” exhibiting unique structural and physiological characteristics, playing significant roles ranging from complement cascade, apoptosis, wound healing to Alzheimer by inhibiting a wide range of proteases. Recently studies have reported its significant roles during various pathologies. Although its full range of potential applications are yet to reveal, its reported implications particularly in CNS insults are making it potential therapeutical approach. Here we aim to draw together the literature shedding light on the potential therapeutical applications of Serpina3n/SERPINA3 in various diseases and a brief comparison between murine Serpina3n and its human ortholog SERPINA3 (α1-antichymotrypsin) accounting their biological roles and significance.

11 March 2021 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
FWFaming Wang
Faming Wang
Yao LuoYao Luo
Yao Luo
LZLe Zhang
Le Zhang
MYMuhammad Younis
Muhammad Younis
LYliudi yuan
liudi yuan
Long non-coding RNAs (lncRNAs) have recently been reported to act as crucial regulators and prognostic biomarkers of human tumorigenesis. Based on microarray data, RP11-301G19.1 was previously identified as an upregulated lncRNA during B cell development. However, the effect of RP11-301G19.1 on multiple myeloma (MM) cells remains unclear. In the present study, the effects of RP11-301G19.1 on tumour progression were ascertained both in vitro and in vivo. Our results demonstrated that RP11-301G19.1 was upregulated in MM cell lines and that its downregulation inhibited the proliferation and cell cycle progression and promoted the apoptosis of MM cells. Bioinformatic analysis and luciferase reporter assay results revealed that RP11-301G19.1 can upregulate the miR-582-5p-targeted gene HMGB2 as a competing endogenous RNA (ceRNA). Furthermore, Western blot results indicated that RP11-301G19.1 knockdown decreased the levels of PI3K and AKT phosphorylation without affecting their total protein levels. Additionally, in a xenograft model of human MM, RP11-301G19.1 knockdown significantly inhibited tumour growth by downregulating HMGB2. Overall, our data demonstrated that RP11-301G19.1 is involved in MM cell proliferation by sponging miR-582-5p and may serve as a therapeutic target for MM.

25 July 2023 in Life Sciences
Verified
Journal Article
Closed access
SSSana Shaikh
Sana Shaikh
MYMuhammad Younis
Muhammad Younis
SYShao Yingying
Shao Yingying
TTTanziela Tanziela
Tanziela Tanziela
LYliudi yuan
liudi yuan

1 May 2021 in Cellular Immunology
Verified
Journal Article
Closed access
FWFaming Wang
Faming Wang
YLYao Luo
Yao Luo
LZLe Zhang
Le Zhang
MYMuhammad Younis
Muhammad Younis
LYliudi yuan
liudi yuan

1 June 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
FWFaming Wang
Faming Wang
MYMuhammad Younis
Muhammad Younis
YLYao Luo
Yao Luo
LZLe Zhang
Le Zhang
LYliudi yuan
liudi yuan

10 March 2021 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
FWFaming Wang
Faming Wang
LZLe Zhang
Le Zhang
YLYao Luo
Yao Luo
QZQingyun Zhang
Qingyun Zhang
YZYueling Zhang
Yueling Zhang
LYliudi yuan
liudi yuan